Edition:
United States

Profile: AtriCure Inc (ATRC.O)

ATRC.O on Consolidated Issue listed on NASDAQ Global Market

21.50USD
19 May 2017
Change (% chg)

$0.32 (+1.51%)
Prev Close
$21.18
Open
$21.20
Day's High
$21.83
Day's Low
$21.16
Volume
224,838
Avg. Vol
210,349
52-wk High
$23.95
52-wk Low
$13.45

AtriCure, Inc., incorporated on October 31, 2000, is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. The Company offers various minimally invasive ablation devices and access tools to facilitate less invasive cardiac and thoracic surgery. The Company has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells enabling technologies, including its Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA). The Company's products are utilized by cardiothoracic surgeons during both open-heart and minimally invasive procedures, either on a concomitant or sole-therapy basis. The Company's Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair.

Product lines for cardiac tissue ablation

The product lines for cardiac tissue ablation include Radio Frequency Ablation Devices and cryoICE Cryoablation System. Physicians use the Isolator Synergy System and related RF devices in both open and minimally invasive procedures. These devices include an Isolator Synergy Ablation and Sensing Unit (ASU), Electrosurgical Unit (ESU) or nContact RF Generator, which are compact power generators. Its RF devices primarily consist of Isolator Synergy and Isolator Synergy Access Clamps, COBRA Fusion Surgical Ablation System, EPi-Sense Guided Coagulation System with VisiTrax Technology, and Multifunctional Pens and Linear Ablation Devices. The cryoICE cryoablation system consists of the cryoICE BOX generator along with a range of cryoICE single use and reusable cryosurgery probes. The cryoICE cryoablation system is used to ablate cardiac tissue for the treatment of cardiac arrhythmias and to provide temporary pain relief to thoracic surgery patients through ablation of peripheral nerves.

Product line for left atrial appendage management

The Company's AtriClip system is designed to exclude the left atrial appendage by mechanically clamping the appendage from the outside, eliminating blood flow between the left atrial appendage and the atrium while avoiding contact with circulating blood. The AtriClip portfolio includes a range of devices with different size clips, as well as different applier lengths and deployment features. The different configurations allow various uses covering both open and minimally invasive surgery.

The Company competes with Medtronic, plc.

Company Address

AtriCure Inc

7555 Innovation Way
MASON   OH   45040-9695
P: +1513.7554100
F: +1513.7554567

Company Web Links